FORMULATION DEVELOPMENT AND EVALUATION OF NOVEL FIXED DOSE COMBINATION OF S (-) PANTOPRAZOLE AND MOSAPRIDE CITRATE BY TABLET IN CAPSULE APPROACH

  • Ruby Singh Emcure pharmaceuticals Pune
  • Srikant Pimple Emcure pharmaceuticals Pune
  • Pravin Maurya Emcure pharmaceuticals Pune
  • Akash Joshi Emcure pharmaceuticals Pune
  • Mohan Salunke Emcure pharmaceuticals Pune

Abstract

Objective: The main objective of the present study was to formulate a fixed dose combination of chirally pure S (-) Pantoprazole and Mosapride citrate tablets. Since no systematic studies on design and development of S (-) Pantoprazole and Mosapride citrate tablets in capsule approach are available in literature, we propose to develop a suitable formulation to characterize in-vitro release profile of both the tablets in capsules. Chirally pure S (-) Pantoprazole tablets were prepared as delayed release and Mosapride citrate tablets were prepared as immediate release tablets.

Methods: Enteric coating was done on S (-) Pantoprazole tablets to modify its release in 6.8 phosphate buffer. In-vitro dissolution of capsule containing both the tablets was performed in two different media, 0.1N HCl and 6.8 phosphate buffer respectively. All Physico-chemical parameters for both the tablets as well as capsules were evaluated individually and were found well within the specified limits.

Result: Initially dissolution was performed in 0.1 N HCl in which immediate release tablet of Mosapride dissolve completely and pantoprazole tablets remains as it is due to enteric coating. Further tablet was placed in 6.8 phosphate buffer in which delayed release tablets of S (-) Pantoprazole gives complete release. Drug product was found stable during accelerated stability studies for 6 month at 40°C/75% RH.

Conclusion: A stable and robust formulation of S (-) Pantoprazole and Mosapride citrate as fixed dose combination was developed and evaluated. Tablet in capsule approach was developed and results were well within the specified limits.

Keywords: S (-) pantoprazole, Mosapride citrate, Modified release, Fixed-dose combination, Delayed release.

Author Biographies

Ruby Singh, Emcure pharmaceuticals Pune

R&D formulation

Research fellow

Srikant Pimple, Emcure pharmaceuticals Pune

R&D Formulation

Director

Pravin Maurya, Emcure pharmaceuticals Pune

R&D Formulation

Sr. Research Scientist

Akash Joshi, Emcure pharmaceuticals Pune

R&D Formulation

Sr. Research Scientist

Mohan Salunke, Emcure pharmaceuticals Pune

R&D formulation

Research fellow

References

1. Wilson B, Babubhai PP, Sajeev MS, Jenita JL, Priyadarshini SR.
Sustained release enteric coated tablets of pantoprazole: Formulation,
in vitro and in vivo evaluation. Acta Pharm 2013;63(1):131-40.
2. Birajdar AS, Meyyanathan SN, Suresh B. Determination of mosapride
and pantoprazole in a fixed-dose combination by UV spectrophotometric
methods and RP-HPLC. Int J Pharm Stud Res 2011;II(II):29-36.
3. Shi S, Klotz U. Proton pump inhibitors: An update of their clinical use
and pharmacokinetics. Eur J Clin Pharmacol 2008;64(10):935-51.
4. Cho YK, Choi MG, Bak YT, Rhee PL, Kim SG, Jung HY, et al.
Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg
in the treatment of reflux esophagitis: A randomized, double-blind
comparative trial. Dig Dis Sci 2012;57(12):3189-94.
5. Jain S, Rathi J. Efficacy and safety of intravenous s-pantoprazole in
the treatment of moderate to severe gastro esophageal reflux disease
(GERD) and/or peptic ulcers. Pharmacol Online 2008;2:733-41.
6. Cao H, Wang MW, Sun LX, Ikejima T, Hu ZQ, Zhao WH.
Pharmacodynamic comparison of pantoprazole enantiomers: Inhibition
of acid-related lesions and acid secretion in rats and guinea-pigs.
J Pharm Pharmacol 2005;57(7):923-7.
7. Siddartha B, Sudheer Babu I, Gupta CR, Panigrahy UP. Analytical
220
Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 217-221
Pimple et al.
method development and validation for simultaneous estimation of
mosapride and pantoprazole in bulk and pharmaceutical dosage form
by RP-HPLC method. J Adv Pharm Educ Res 2014;4(2):186-92.
8. Shaikh SS, Shaikh SA, Shukoor MA, Padalkar AN. Formulation
development of orodispersible tablets of mosapride citrate using
different super disintegrants and their evaluation. Asian J Biomed
Pharm Sci 2012;2(11):32-40.
9. Manasa G, Anusha N. Development and validation of RP-HPLC method
for the simultaneous estimation of pantoprazole and mosapride in
capsule dosage form. Int J Pharm Accuracy Pharm Sci 2012;4(5):293-9.
10. Dasa A, Sathyamoorthy N, Garikapati D. Delayed release formulation
of pantoprazole using sureteric aqueous dispersion system. Pharm Lett
2013;5(5):175-86.
11. Chakraborty S, Sarkar S, Debnath SK. Formulation development and
evaluation of pantoprazole enteric coated tablets. Int J ChemTech Res
2009;1(3):663-6.
12. Pai VG, Pai NV, Thacker HP, Shinde JK, Mandora VP, Erram SS.
Comparative clinical trial of S-pantoprazole versus racemic
pantoprazole in the treatment of gastro-esophageal reflux disease.
World J Gastroenterol 2006;12(37):6017-20.
Statistics
250 Views | 322 Downloads
How to Cite
Singh, R., S. Pimple, P. Maurya, A. Joshi, and M. Salunke. “FORMULATION DEVELOPMENT AND EVALUATION OF NOVEL FIXED DOSE COMBINATION OF S (-) PANTOPRAZOLE AND MOSAPRIDE CITRATE BY TABLET IN CAPSULE APPROACH”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 5, Sept. 2015, pp. 224-8, https://innovareacademics.in/journals/index.php/ajpcr/article/view/7333.
Section
Original Article(s)